CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
A second PD-1 antibody, camrelizumab, also lengthened progression-free survival when added to gemcitabine and cisplatin in metastatic nasopharyngeal cancer, confirming that chemo-immunotherapy is the new first-line standard.
Overview
Chinese multicentre randomised double-blind phase 3 trial of 263 patients with recurrent or metastatic nasopharyngeal carcinoma assigned to camrelizumab or placebo with gemcitabine and cisplatin, followed by maintenance.
Median progression-free survival was 9.7 months with camrelizumab against 6.9 months with placebo (hazard ratio 0.54), with a higher response rate; reactive cutaneous capillary endothelial proliferation, characteristic of camrelizumab, was common but mostly mild.
- Median progression-free survival 9.7 months with camrelizumab plus chemotherapy versus 6.9 months with chemotherapy alone; hazard ratio 0.54.
Together with JUPITER-02 and RATIONALE-309, this trial made PD-1 blockade plus gemcitabine-cisplatin the first-line standard for metastatic nasopharyngeal carcinoma.
- Conducted entirely in China.
- Overall survival data were immature at publication.
Similar pages
not linked directly; found by shared links- Key paperGemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma
Shares Gemcitabine + cisplatin, Recurrent and metastatic nasopharyngeal carcinoma.
- Key paperJUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma
Shares Gemcitabine + cisplatin, Recurrent and metastatic nasopharyngeal carcinoma.
- TrialJUPITER-02
Shares CAPTAIN-1st, Recurrent and metastatic nasopharyngeal carcinoma.
- CancerLocoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Shares Camrelizumab, Gemcitabine + cisplatin, Recurrent and metastatic nasopharyngeal carcinoma.
- CancerNasopharyngeal carcinoma
Shares CAPTAIN-1st, Camrelizumab, Gemcitabine + cisplatin, Recurrent and metastatic nasopharyngeal carcinoma.